INDEPENDENT. INTERNATIONAL. LEADERS.
The Research Management Committee (RMC) is made up of independent members whose primary role is to evaluate research proposals and actively help BioCanRx monitor the progress of its projects. The RMC will build and maintain a robust, competitive research portfolio founded on scientific excellence and network goals. All RMC funding and budget recommendations go to the Board of Directors for approval.
In order to avoid potential conflicts of interest, the voting RMC is composed of independent and primarily international experts in biotherapeutics.
Membership
 |
 |
 |
 |
| Dr. Dmitriy Zamarin Medical Oncologist, Section Head, Gynecologic Medical Oncology at Icahn School of Medicine at Mount Sinai |
Dr. Awen Gallimore Professor, Immunology, Infection and Immunity, Cardiff University |
Dr. Jeffrey Hoch Professor, Department of Public Health Sciences, UC Davis |
Dr. Sumithra Mandrekar Professor of Biostatistics and Oncology at the Mayo Clinic (USA) |
 |
 |
 |
 |
| Dr. Alan Melcher Professor of Translational Immunotherapy, The Institute of Cancer Research, Chester Beatty Laboratories, London (UK) |
Dr. Isabelle Rivière Vice President, Head of Oncology Cell Therapy Technologies and Product Engine, Takeda |
Dr. Cliona Rooney Professor, Baylor College of Medicine (USA) |
Dr. Bruce Seet Head of Medical Affairs (Canada) at Novavax |
 |
 |
 |
|
| Dr. Len Seymour Professor of Gene Therapy, University of Oxford |
Dr. Alison Betof-Warner Assistant Professor of Medicine (Oncology), Stanford University School of Medicine |
Dr. Guy Ungerechts Deputy Director of the Medical Oncology Department at the Heidelberg University Hospital and National Center for Tumor Diseases (NCT) Heidelberg |
EX-OFFICIO MEMBERS (NON-VOTING)
Dr. John Bell
BioCanRx Scientific Director
Senior Scientist, the Ottawa Hospital Research Institute
Professor, uOttawa
Dr. Kelvin Chan
Associate Scientist, Sunnybrook Health Sciences Centre (Canada)
Dr. Douglas Mahoney
Associate Professor of Microbiology, Immunology, and Infectious Disease
Associate Director, Basic and Translational Research, Charbonneau Cancer Institute
Scientific Director, Alberta Cell Therapy and Immune Oncology (ACTION) Initiative
Director, Riddell Centre for Cancer Immunotherapy
Dr. Brad Nelson
BioCanRx Theme Leader
Director and Distinguished Scientist, Deeley Research Centre, BCCA
Professor, Biochemistry and Microbiology, University of Victoria
Dr. Claude Perreault
Principal Investigator, IRIC
Professor, Faulty of Medicine, Université de Montréal
Hematologist, Maisonneuve-Rosemont Hospital
Jean-Louis Brochu
Director, Intellectual Property and Communication, IRICoR
Narjes Achach
Intellectual Property Analyst, IRICoR
OBSERVERS
Dr. Stéphanie Michaud
President and CEO, BioCanRx
Megan Mahoney, PhD
Director, Scientific Affairs and Training Programs
Julie Jonkhans, PhD
Training and Research Manager
